Logo image of KPTI

KARYOPHARM THERAPEUTICS INC (KPTI) Stock Fundamental Analysis

NASDAQ:KPTI - Nasdaq - US48576U1060 - Common Stock - Currency: USD

0.5984  -0.01 (-1.9%)

After market: 0.609 +0.01 (+1.77%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KPTI. KPTI was compared to 571 industry peers in the Biotechnology industry. KPTI has a bad profitability rating. Also its financial health evaluation is rather negative. KPTI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KPTI had negative earnings in the past year.
KPTI had a negative operating cash flow in the past year.
KPTI had negative earnings in each of the past 5 years.
KPTI had a negative operating cash flow in each of the past 5 years.
KPTI Yearly Net Income VS EBIT VS OCF VS FCFKPTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

KPTI has a Return On Assets (-46.17%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -46.17%
ROE N/A
ROIC N/A
ROA(3y)-48.77%
ROA(5y)-55.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KPTI Yearly ROA, ROE, ROICKPTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 800

1.3 Margins

The Gross Margin of KPTI (95.85%) is better than 96.45% of its industry peers.
In the last couple of years the Gross Margin of KPTI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for KPTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.3%
GM growth 5YN/A
KPTI Yearly Profit, Operating, Gross MarginsKPTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K -50K

More info and screens

2

2. Health

2.1 Basic Checks

KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for KPTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KPTI Yearly Shares OutstandingKPTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
KPTI Yearly Total Debt VS Total AssetsKPTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

KPTI has an Altman-Z score of -11.82. This is a bad value and indicates that KPTI is not financially healthy and even has some risk of bankruptcy.
KPTI has a Altman-Z score of -11.82. This is in the lower half of the industry: KPTI underperforms 78.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.82
ROIC/WACCN/A
WACC4.28%
KPTI Yearly LT Debt VS Equity VS FCFKPTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.00 indicates that KPTI has no problem at all paying its short term obligations.
KPTI has a worse Current ratio (3.00) than 65.72% of its industry peers.
A Quick Ratio of 2.93 indicates that KPTI has no problem at all paying its short term obligations.
KPTI has a worse Quick ratio (2.93) than 64.48% of its industry peers.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 2.93
KPTI Yearly Current Assets VS Current LiabilitesKPTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.40% over the past year.
EPS 1Y (TTM)46.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.5%

3.2 Future

The Earnings Per Share is expected to grow by 18.64% on average over the next years. This is quite good.
Based on estimates for the next years, KPTI will show a very strong growth in Revenue. The Revenue will grow by 25.91% on average per year.
EPS Next Y-9.39%
EPS Next 2Y8.3%
EPS Next 3Y17.98%
EPS Next 5Y18.64%
Revenue Next Year7.35%
Revenue Next 2Y14.28%
Revenue Next 3Y23.91%
Revenue Next 5Y25.91%

3.3 Evolution

KPTI Yearly Revenue VS EstimatesKPTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KPTI Yearly EPS VS EstimatesKPTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KPTI. In the last year negative earnings were reported.
Also next year KPTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPTI Price Earnings VS Forward Price EarningsKPTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPTI Per share dataKPTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as KPTI's earnings are expected to grow with 17.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.3%
EPS Next 3Y17.98%

More info and screens

0

5. Dividend

5.1 Amount

KPTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (2/21/2025, 8:00:02 PM)

After market: 0.609 +0.01 (+1.77%)

0.5984

-0.01 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners49.37%
Inst Owner Change-95.21%
Ins Owners0.81%
Ins Owner Change0.49%
Market Cap75.51M
Analysts83.08
Price Target4.59 (667.05%)
Short Float %17.03%
Short Ratio20.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.14%
Min EPS beat(2)3.03%
Max EPS beat(2)149.25%
EPS beat(4)3
Avg EPS beat(4)36.09%
Min EPS beat(4)-13.96%
Max EPS beat(4)149.25%
EPS beat(8)5
Avg EPS beat(8)19.62%
EPS beat(12)9
Avg EPS beat(12)32.34%
EPS beat(16)11
Avg EPS beat(16)24.42%
Revenue beat(2)2
Avg Revenue beat(2)8.28%
Min Revenue beat(2)0.62%
Max Revenue beat(2)15.94%
Revenue beat(4)2
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-6.55%
Max Revenue beat(4)15.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.17%
Revenue beat(12)8
Avg Revenue beat(12)21.36%
Revenue beat(16)10
Avg Revenue beat(16)18.37%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-5.9%
EPS NQ rev (3m)-5.9%
EPS NY rev (1m)-2.51%
EPS NY rev (3m)4.63%
Revenue NQ rev (1m)-8.32%
Revenue NQ rev (3m)-8.32%
Revenue NY rev (1m)-0.95%
Revenue NY rev (3m)-2.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS1.18
BVpS-1.27
TBVpS-1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.85%
FCFM N/A
ROA(3y)-48.77%
ROA(5y)-55.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.3%
GM growth 5YN/A
F-Score2
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.52%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3
Quick Ratio 2.93
Altman-Z -11.82
F-Score2
WACC4.28%
ROIC/WACCN/A
Cap/Depr(3y)15.31%
Cap/Depr(5y)16.61%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-9.39%
EPS Next 2Y8.3%
EPS Next 3Y17.98%
EPS Next 5Y18.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.5%
Revenue Next Year7.35%
Revenue Next 2Y14.28%
Revenue Next 3Y23.91%
Revenue Next 5Y25.91%
EBIT growth 1Y-0.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.67%
OCF growth 3YN/A
OCF growth 5YN/A